We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+49.42%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.93B
AUM Growth
+$917M
Cap. Flow
-$123M
Cap. Flow %
-3.14%
Top 10 Hldgs %
73.9%
Holding
131
New
35
Increased
30
Reduced
17
Closed
20

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$64.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$54.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26M
4
TNGX icon
Tango Therapeutics
TNGX
+$23.5M
5
MRUS
Merus
MRUS
+$18.5M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$295M
2
CYTK icon
Cytokinetics
CYTK
+$54.7M
3
ARGX icon
argenx
ARGX
+$44.3M
4
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.8M
5
FOLD
Amicus Therapeutics
FOLD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 50.26%
2 Consumer Discretionary 47.87%
3 Technology 0.53%
4 Real Estate 0.1%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
26
Viking Therapeutics
VKTX
$3.88B
$20.8M 0.53%
+253,863
New +$11.3M
MRUS
27
DELISTED
Merus
MRUS
$20.5M 0.52%
+455,081
New +$18.5M
NAMS icon
28
NewAmsterdam Pharma
NAMS
$3.26B
$18.9M 0.48%
+800,000
New +$16.2M
TNGX icon
29
Tango Therapeutics
TNGX
$4.21B
$17.4M 0.44%
+2,194,841
New +$23.5M
ARWR icon
30
CALL
Arrowhead Research
ARWR
$12.1B
$17.2M 0.44%
600,000
+400,000
+200% +$12.8M
SLRN
31
DELISTED
ACELYRIN
SLRN
$16.2M 0.41%
2,405,143
-630,745
-21% -$4.79M
ALPN
32
DELISTED
Alpine Immune Sciences Inc
ALPN
$16.1M 0.41%
405,784
+355,025
+699% +$10.5M
CNTA
33
DELISTED
Centessa Pharmaceuticals
CNTA
$16M 0.41%
1,412,500
+400,000
+40% +$3.79M
GOSS icon
34
Gossamer Bio
GOSS
$101M
$15.7M 0.4%
13,308,968
+1,250,000
+10% +$1.38M
EWTX icon
35
Edgewise Therapeutics
EWTX
$4.28B
$14.8M 0.38%
+811,718
New +$12.9M
SYRS
36
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$13.4M 0.34%
2,505,013
– –
SE icon
37
Sea Limited
SE
$66.4B
$12.8M 0.33%
237,500
-134,500
-36% -$6.19M
LXEO icon
38
Lexeo Therapeutics
LXEO
$338M
$12.6M 0.32%
801,716
+198,281
+33% +$3.1M
ATXS
39
DELISTED
Astria Therapeutics
ATXS
$12.4M 0.32%
+884,214
New +$11M
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$11.9M 0.3%
1,011,776
-1,014,588
-50% -$13M
GBIO
41
DELISTED
Generation Bio
GBIO
$11.5M 0.29%
283,059
+1,640
+0.6% +$38.6K
XENE icon
42
Xenon Pharmaceuticals
XENE
$6.1B
$10.9M 0.28%
+253,387
New +$11.7M
CLDX icon
43
Celldex Therapeutics
CLDX
$2.94B
$10.6M 0.27%
+253,000
New +$10.4M
TSHA icon
44
Taysha Gene Therapies
TSHA
$1.61B
$10.6M 0.27%
3,687,548
+24,444
+0.7% +$50.9K
DNLI icon
45
Denali Therapeutics
DNLI
$3.79B
$10.3M 0.26%
502,899
-300,000
-37% -$5.64M
APGE icon
46
Apogee Therapeutics
APGE
$10.1B
$10.1M 0.26%
+152,500
New +$6.66M
ERAS icon
47
Erasca
ERAS
$6.15B
$9.73M 0.25%
4,721,194
– –
AGEN
48
Agenus
AGEN
$276M
$9.07M 0.23%
781,562
– –
SEER icon
49
Seer Inc
SEER
$114M
$9.03M 0.23%
4,750,000
– –
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.46B
$8.31M 0.21%
+177,932
New +$8.39M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2024 Portfolio in Review

As of Q1 2024, Artal Group held 131 positions worth $3.93B, up 30% from $3.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Artal Group withdrew a net $123M in Q1 2024, closing 20 positions and reducing 17 holdings. Its most notable exit was argenx, an estimated $44.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 50% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Crinetics Pharmaceuticals worth $65.1M.

  • Artal Group's largest Q1 2024 buy was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M.
  • Artal Group added most to Arrowhead Research in Q1 2024, an estimated $64.3M increase.
  • Artal Group's biggest Q1 2024 reduction was CAVA Group, cutting an estimated $295M.
  • Artal Group fully exited argenx in Q1 2024, selling an estimated $44.3M.
  • Artal Group's ten largest holdings make up 74% of its $3.93B portfolio in Q1 2024.
  • Artal Group opened 35 new positions and closed 20 in Q1 2024.
  • Artal Group's portfolio value rose 30% quarter-over-quarter to $3.93B.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.